We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
Cytovance Biologics and PolyPeptide Announce Collaboration for Microbial and Mammalian-Expressed Peptide Drugs
13 Jan 2025 - This collaboration offers an integrated solution for customers seeking to outsource the development and manufacturing of microbial and mammalian-expressed peptide drugs, with scalable options that address […]
Read moreDoubling of production capacity at the manufacturing site in Malmö
8 Jan 2025 - Baar, 8 January 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the planned doubling of solid-phase peptide […]
Read moreLarge-scale SPPS capacity in Braine-l’Alleud starts production
16 Dec 2024 - Baar, 16 December 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the start of production with the […]
Read morePolyPeptide appoints Chief Commercial Officer
8 Aug 2024 - Baar, 8 August 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the appointment of […]
Read morePolyPeptide and Donaldson collaborate to develop solvent recovery system for peptide purification
13 May 2024 - MINNEAPOLIS / TORRANCE, Calif. May 13, 2024 – Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of innovative filtration and separation products and solutions, and […]
Read morePolyPeptide announces results of the annual General Meeting 2024
10 Apr 2024 - Baar, 10 April 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced that the shareholders […]
Read morePolyPeptide publishes invitation to the annual General Meeting 2024
19 Mar 2024 - Baar, 19 March 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, published today the invitation to […]
Read morePolyPeptide signs scientific collaboration agreement
31 Oct 2023 - Strasbourg, 31 October 2023 – PolyPeptide today announced the signing of a collaboration agreement with the Peptide Sciences Laboratory of the University of KwaZulu-Natal (UKZN) in […]
Read morePolyPeptide secures revolving credit facility
2 Oct 2023 - Baar, 2 October 2023 – PolyPeptide Group AG (SIX: PPGN) announces the signing of a revolving credit facility agreement with Credit Suisse, Danske Bank and Zürcher […]
Read more